f Thematic Selection: The Comorbidity of Mental Disorders and Metabolic Disorders (Part I)

References

1. VancampfortD. FirthJ. SchuchF.B. RosenbaumS. MugishaJ. HallgrenM. ProbstM. WardP.B. GaughranF. De HertM. CarvalhoA.F. StubbsB. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major de-pressive disorder: a global systematic review and meta‐analysis.World Psychiatry201716330831510.1002/wps.20458 28941119
   [Google Scholar]
2. FirthJ. SiddiqiN. KoyanagiA. SiskindD. RosenbaumS. GalletlyC. AllanS. CaneoC. CarneyR. CarvalhoA.F. ChattertonM.L. CorrellC.U. CurtisJ. GaughranF. HealdA. HoareE. JacksonS.E. KiselyS. LovellK. MajM. McGorryP.D. MihalopoulosC. MylesH. O’DonoghueB. PillingerT. SarrisJ. SchuchF.B. ShiersD. SmithL. SolmiM. SuetaniS. TaylorJ. TeasdaleS.B. ThornicroftG. TorousJ. UsherwoodT. VancampfortD. VeroneseN. WardP.B. YungA.R. KillackeyE. StubbsB. The lancet psychiatry commission: A blueprint for protecting physical health in people with mental illness.Lancet Psychiatry20196867571210.1016/S2215‑0366(19)30132‑4 31324560
   [Google Scholar]
3. NielsenR.E. BannerJ. JensenS.E. Cardiovascular disease in patients with severe mental illness.Nat. Rev. Cardiol.202118213614510.1038/s41569‑020‑00463‑7 33128044
   [Google Scholar]
4. LambertA.M. ParrettiH.M. PearceE. PriceM.J. RileyM. RyanR. Tyldesley-MarshallN. AvşarT.S. MatthewmanG. LeeA. AhmedK. OdlandM.L. CorrellC.U. SolmiM. MarshallT. Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis.PLoS Med.2022194e100396010.1371/journal.pmed.1003960 35439243
   [Google Scholar]
5. PenninxB.W.J.H. LangeS.M.M. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications.Dialogues Clin. Neurosci.2018201637310.31887/DCNS.2018.20.1/bpenninx 29946213
   [Google Scholar]
6. ZengC. YangP. CaoT. GuY. LiN. ZhangB. XuP. LiuY. LuoZ. CaiH. Gut microbiota: An intermediary between metabolic syndrome and cognitive deficits in schizophrenia.Prog. Neuropsychopharmacol. Biol. Psychiatry202110611009710.1016/j.pnpbp.2020.110097 32916223
   [Google Scholar]
7. McGuinnessA.J. DavisJ.A. DawsonS.L. LoughmanA. CollierF. O’HelyM. SimpsonC.A. GreenJ. MarxW. HairC. GuestG. MohebbiM. BerkM. StupartD. WattersD. JackaF.N. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia.Mol. Psychiatry20222741920193510.1038/s41380‑022‑01456‑3 35194166
   [Google Scholar]
8. CuiD. LiZ. XingM. ShengJ. CuiM. SuY. ZhangC. ChenX. FangY. Differing prevalence and correlates of metabolic syndromes between chlorpromazine and clozapine: A 10-year retrospective study of a male chinese cohort.Curr. Neuropharmacol.202220101969197710.2174/1570159X20666220302153123 35236263
   [Google Scholar]
9. OsbornD. BurtonA. HunterR. MarstonL. AtkinsL. BarnesT. BlackburnR. CraigT. GilbertH. HeinkelS. HoltR. KingM. MichieS. MorrisR. MorrisS. NazarethI. OmarR. PetersenI. PevelerR. PinfoldV. WaltersK. Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: A cluster randomised controlled trial.Lancet Psychiatry20185214515410.1016/S2215‑0366(18)30007‑5 29396118
   [Google Scholar]
10. HalabitskaI. PetakhP. KamyshnaI. OksenychV. KainovD.E. KamyshnyiO. The interplay of gut microbiota, obesity, and depression: insights and interventions.Cell. Mol. Life Sci.202481144310.1007/s00018‑024‑05476‑w 39476179
    [Google Scholar]
11. GroenR.N. de ClercqN.C. NieuwdorpM. HoendersH.J.R. GroenA.K. Gut microbiota, metabolism and psychopathology: A critical review and novel perspectives.Crit. Rev. Clin. Lab. Sci.201855428329310.1080/10408363.2018.1463507 29673295
    [Google Scholar]
12. MacKayM. YangB.H. DursunS.M. BakerG.B. The gut-brain axis and the microbiome in anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder.Curr. Neuropharmacol.202422586688310.2174/1570159X21666230222092029 36815632
    [Google Scholar]
13. GuoT.L. ChenY. XuH.S. McDonoughC.M. HuangG. Gut microbiome in neuroendocrine and neuroimmune interactions: The case of genistein.Toxicol. Appl. Pharmacol.202040211513010.1016/j.taap.2020.115130 32673657
    [Google Scholar]
14. ArillottaD. FlorestaG. GuirguisA. CorkeryJ.M. CatalaniV. MartinottiG. SensiS.L. SchifanoF. GLP-1 receptor agonists and related mental health issues: Insights from a range of social media platforms using a mixed-methods approach.Brain Sci.20231311150310.3390/brainsci13111503 38002464
    [Google Scholar]
15. AuH.C.T. ZhengY.J. LeG.H. WongS. PhanL. TeopizK.M. KwanA.T.H. RheeT.G. RosenblatJ.D. HoR. McIntyreR.S. A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.J. Affect. Disord.202537032132710.1016/j.jad.2024.11.019 39515485
    [Google Scholar]
16. FatimaA. RasoolS. DeviS. TalhaM. WaqarF. NasirM. KhanM.R. Ibne Ali JaffariS.M. HaiderA. ShahS.U. SapnaF.N.U. VarrassiG. KhatriM. KumarS. MohamadT. Exploring the cardiovascular benefits of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors: Expanding horizons beyond diabetes management.Cureus2023159e4624310.7759/cureus.46243 37908957
    [Google Scholar]